SB225002 has been confirmed to inhibit tumor growth and significantly suppress TKI-resistant CML cells in mouse xenotransplantation models, indicating that CXCR2-targeted inhibitors represent a promising new therapeutic strategy for CML and TKI-resistant CML [22]. Here, CXCR2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.